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respectively, which shows that usage of drugs associated with higher SHE risks var-
ies between countries. E.g. in type 1 DM 42.65% patients in Hungary use basal-bolus 
with human basal (related to 1.1 events/person-year), while only 8% in Croatia. In 
type 2 DM 9.37% patients in Hungary use basal-bolus regimen with basal human 
insulin (0.6 events /person-year), and only 0.5% in Croatia. ConClusions: Rates 
of SHEs differ for T1, T2 and drug regimens. Various treatment schemes prevail in 
analysed countries, which result in different total (estimated) risks. However, other 
factors may impact the actual SHE incidence and motivate treatment selection in 
the first place. Therefore the results should not be used to draw conclusions regard-
ing the overall quality of DM patients care.
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objeCtives: The Syreon model was developed to predict the long term effects 
of screening, treatment and control of type 2 diabetes. After a successful internal 
and external validation the model is capable of analyzing the consequences of 
different macro-level policy interventions. The aim of this analysis was to assess 
the cost-effectiveness of the introduction of a risk stratified population screening 
compared to no screening in Hungary. Methods: The screening program consists 
of two major elements. The first covers the use of the internationally validated 
FINDRISC questionnaire to identify people at high risk of diabetes. Answers to the 
questionnaire are simulated based on individual characteristics. The second part of 
the module refers the high risk (FINDRISC score > = 12) population to oral glucose 
tolerance test. After completion of the screening program, patients enter the disease 
progression and treatment module. The screening process can be repeated over 
defined periods, e.g. every 3 years. Results: Introduction of 3 yearly risk stratified 
screening for 50-60 age groups with not known diabetes was estimated to result 
in an incremental cost-effectiveness ratio of 32 000 PPP $/QALY. The results were 
sensitive to the starting age of the target group, the frequency and the stopping age 
of the organized screening. ConClusions: Risk stratified screening program was 
predicted to be cost-effective compared with no screening in Hungary in certain 
age-groups. Early diagnosis of type 2 diabetes contributes to earlier treatment that 
results in better health and less complications.
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objeCtives: The total estimated cost of diagnosed diabetes in the United States 
(US) in 2012 was $245 billion. Although the cost of diabetic supplies is reported to 
be less than 2% of total expenditures, the fractional cost contribution of the most 
common insulin delivery devices, critical to disease management, remain unknown. 
The objective of this study is to understand the cost distribution among pharmacy 
benefit diabetic supplies and quantify the impact of manual insulin delivery devices 
on the overall cost of diabetes in the US. Methods: A cross-sectional analysis 
of the 2010 Medical Expenditure Panel Survey (MEPS) database was conducted. 
Diabetic supplies were identified from the linked prescription file and categorized 
through identification of National Drug Codes, prescription names and prescription 
form variables. Non-pharmacy benefits including insulin pumps were excluded. 
Expenditures were calculated as the sum source payments and reported in 2012 
dollars. Weighted mean expenditures per diabetic were calculated using SAS 9.2 
SURVEYMEANS procedure. A prevalence-based approach was used to extrapolate 
to the 2012 U.S. diabetic population. Results: 2,440 diabetics were included. The 
sample was 55% female and 12% uninsured with a mean age of 58 (±16.48). The 
estimated total diabetic supply expenditures in the U.S. in 2012 were $3,598,491,566. 
Test strips were the largest contributors to this category (74.7%, $2,689,696,646) fol-
lowed by insulin pens (7.1%), pen needles (6.8%) and syringes (5.1%). Insulin delivery 
devices (limited to insulin pen needles and insulin syringes) contribute 0.24% of 
U.S. direct medical expenditures and 0.17% of the total U.S. expenditures on diabe-
tes. ConClusions: These results highlight the fractional contribution that diabetic 
supplies, and more specifically manual insulin delivery devices, contribute to the 
overall costs attributed to diabetes in the U.S. Further research should consider 
the positive cost implications that such devices may have on diabetes outcomes.
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objeCtives: Our objectives were to understand patient experience with and uti-
lization of manufacturer-sponsored patient support programs for type 2 diabetes 
(T2DM) injectable therapy. Methods: Data for these analyses were drawn from 
a larger cross-sectional survey evaluating treatment adherence and persistence 
among T2DM patients in the US age ≥ 18 who had been prescribed an injectable 
medication. Patients were recruited from a general-population on-line panel, and 
recruitment was stratified by medication and discontinuation status. Analyses are 
limited to the 3 medications for which ≥ 25 respondents reported using the cor-
responding patient support program: exenatide once weekly, liraglutide, insulin 
glargine. Proportions were calculated using a drop-out weighting method. Results: 
Bydureon Steady Support (BSS) was utilized by 26% of exenatide once weekly 
patients (51/200), 14% of liraglutide patients (83/598) utilized Victoza Care (VC), 
and 10% of insulin glargine patients 48/488) utilized Lantus Connection (LC). Those 
inadequately controlled by metformin (MET) monotherapy. This study aimed to 
understand the treatment regimens of Medicare Advantage with Prescription Drug 
coverage (MAPD) patients in a large national health plan who newly initiate MET 
monotherapy, and assess factors associated with changes in therapy in the 12 
months after MET initiation. Methods: This was a retrospective cohort analysis 
of medical and pharmacy claims of 17,527 MAPD members aged 18-89, with ≥ 1 
medical claim containing a primary diagnosis or ≥ 2 medical claims containing a 
secondary diagnosis of T2DM, and with an initial prescription fill for MET between 
1/1/2008 and 9/30/2011. Demographic and clinical characteristics were analyzed 
using descriptive statistics; factors associated with treatment changes were exam-
ined using Cox proportional hazard regression models. Results: 59% of MAPD 
patients (mean age 69.6 years) remained on MET monotherapy with no changes. 
Discontinuation was the most common treatment change (33%), followed by addi-
tion (5%), and switching (2%). Of patients who discontinued treatment (median 
time to discontinuation= 90 days), 61% did not re-initiate any diabetic treatment 
during the 12 month follow-up period. Among those who added or switched to 
other antidiabetics, sulfonylureas were the most commonly-added or switched-
to drugs. Discontinuation was predicted by being female (hazard ratio [HR] 1.06, 
[1.003;1.12]95%CI), having more comorbidities (HR 1.00, [1.01;1.04]95%CI) or a diag-
nosis of depression (HR 1.18, [1.08;1.27]95%CI) in the 12 months before initiating 
MET; in MAPD aged ≥ 65 (n= 14,389), discontinuation was predicted by a higher 
baseline daily average consumption (DACON) of MET (HR 1.00, [1.0002;1.0006]95%CI).  
ConClusions: Discontinuation of MET was the most common treatment change 
in this population. Being female, having a higher baseline DACON of MET, more 
comorbidities or a diagnosis of depression were all predictors of discontinuation.
PDB121
assessing the relationshiP Between ranDom gluCose anD all-Cause 
mortality
Tang J.1, Saith S.2, Al Memari S.A2, Aldhaheri A.2, Kohut A.2
1University of California, San Francisco, CA, USA, 2Harvard University, Boston, MA, USA
objeCtives: Early metabolic abnormalities that precede diabetes (impaired fast-
ing glucose and impaired glucose tolerance) are associated with increased mortal-
ity. Our study aimed to assess the relationship between random glucose levels 
and development of all-cause mortality, specifically considering the differences 
between normal, high-normal glucose, pre-diabetes and diabetes. Methods: A 
retrospective cohort study using a limited dataset from the Framingham Heart 
Study was employed. Baseline-period was in 1956, each patient was followed 
24 years. Random glucose was grouped into normal, high-normal, pre-diabetes, 
and diabetes. Ages, gender, body mass index, and blood pressure were examined. 
Outcome measure was all-cause mortality. Bivariate and multivariate cox propor-
tional hazards regression models controlling for demographics and risk factors 
were performed to compare the risk of death between different random glucose 
levels. Results: The study cohort consisted of 3,270 survey patients with a mean 
age 50(±8.68), of which 1,825(55.8%) were female. During the follow-up period, 1,178 
patients deceased. The average follow-up time was 20 years; while average sur-
vival time for patients who deceased was 14 years. Compared to normal random 
glucose, high-normal (Hazard Ratio[HR]:1.486; Confidence Interval[CI]:1.24 –1.77), 
pre-diabetes (HR:3.328; CI:2.237–4.951) and diabetes (HR:5.314; CI:3.754–7.523) were 
significantly associated with increased risk of all-cause death in the bivariate Cox 
regression model. In adjusted model, high-normal glucose level (HR:1.216; CI:1.019–
1.45), pre-diabetes(HR:2.458; CI:1.647–3.667), and diabetes (HR:3.164; CI:2.214– 4.521) 
were significantly associated with increased risk of death compared to normal 
glucose group; age and hypertensive systolic blood pressure were associated with 
increased risk of all-cause death; while female gender was significantly associated 
with decreased risk of death. ConClusions: Random glucose alone can predict 
risk and even high-normal levels are associated with increased mortality. Our find-
ings are of value especially when considering cost-effective strategies in screening 
underserved populations throughout the globe, where medical resources are scarce 
and fasting glucose levels are difficult to obtain.
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objeCtives: Severe (requiring another person’s assistance) hypoglycaemic events 
(SHEs) matter from clinical and economic perspective. Various risk factors are men-
tioned in the literature (drugs used, patients’ adherence, diet, exercise). We aimed 
to compare diabetes mellitus (DM) treatment patterns in Croatia, Czech Republic, 
Hungary, Poland and Slovenia with respect to the resulting risk of SHE. Methods: 
We performed a systematic review to assess the drug related annual SHE rates for 
various treatments (shown in past ISPOR meetings) defined depending on using oral 
antidiabetic medications, sulfonylureas, insulins–split into basal-bolus/biphasic, 
and analogues/human. Epidemiological data were based on national registries, pre-
scription databases, published studies, questionnaire surveys. Market shares were 
based on IMS data (Croatia, Czech Republic, Poland), National Health Insurance Fund 
(Hungary), prescription database (Slovenia). Results: Using SHE rates estimates 
for individual treatment schemes and epidemiological and market data we arrived 
at the following estimates of the annual total number of SHEs: Croatia – 16,975, 
Czech Republic – 80,884, Hungary – 62,282, Poland – 217,711, and Slovenia – 9,291. 
When expressed per one DM patient we got annually: 0.078, 0.117, 0.143, 0.120, 0.096, 
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to 6% between 2008–2013. It still lags behind NICE’s 2008 benchmark of 12%, in addi-
tion to uptake in other Western countries. We aimed to understand why the UK has 
comparatively low pump uptake. Methods: We performed a structured PubMed 
literature review using search terms “Continuous subcutaneous insulin infusion” 
AND glycaemi* OR hypoglycaemi* OR “costs and cost analysis[MeSH]”, published 
after 01/01/2008. Captured articles were sifted; excluding irrelevant articles, or those 
not in English. Other relevant reports were captured by horizon scanning. Results: 
Our search terms captured 113 articles. Reviewing reports meeting the inclusion 
criteria revealed that since 2008, additional studies contribute evidence supporting 
CSII efficacy in improving HbA1c, glycaemic variability and incidence of hypogly-
caemia compared to MDI; in addition to being well-tolerated by patients. Recent 
cost-analyses suggest that CSII remains cost-effective, especially when increasing 
baseline HbA1c, hypoglycaemia avoidance, or pump life expectancy. Furthermore, 
there may be a low availability of specialised nurses, dieticians and other clinicians 
that NICE recommends are required to form part of a CSII-specialised multi-disci-
plinary team. ConClusions: It is surprising that given the amount of evidence 
supporting the efficacy, safety and cost-effectiveness of CSII, uptake of pumps by 
T1DM patients remains low in the UK. It is interesting that current evidence may be 
undermined by poor availability of clinical staff specialised in CSII, thus preventing 
new patients from effectively managing their condition.
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objeCtives: To evaluate treatment patterns of Type 2 diabetes (T2DM) patients 
initiating glucagon-like peptide-1 receptor agonists (GLP-1) in Canada. Methods: 
Adult T2DM patients initiating a GLP-1 between January 2010 and December 2011 
were identified using the IMS retail pharmacy database (LRx). Initiation was termed 
‘index date’. Eligible patients were naïve to GLP-1 class and had ≥ 180 days pre-index 
(with ≥ 1 oral anti-hyperglycemic agent used) and ≥ 360 days post-index of patient 
and data stability. Patients were followed through December 2012. Treatment pat-
terns over the variable-follow-up, and average daily dose of the index therapy 
while persistent were assessed. Outcomes were summarized overall and by GLP-1 
therapy: exenatide twice-daily (exBID) or liraglutide (LIRA). Results: 12,417 GLP-1 
initiators, 242 exBID and 12,175 LIRA, were included, with mean (SD) follow-up of 
14.9(1.5) and 20.6(4.8) months, respectively. Overall, approximately half were male 
(49.9%) with mean (SD) age of 57.2(9.9) years at index. 70.1% GLP-1 initiators were 
privately insured; 5.0% publicly covered and 21.4% were based on out-of-pocket 
payments. In the 180 day pre-index period, 33.7% of GLP-1 initiators used two 
concomitant anti-hyperglycemic agents, 27.9% used three, 19.7% used only one, 
and 8.4% used > 3. The most frequent concomitant medications in the pre-index 
were biguanides (75%), sulfonylureas (43.9%), and DPP-IV inhibitors (24.7%). At 
index, 35.9% of GLP-1 initiators used one concomitant anti-hyperglycemic agent 
in addition to the initiated GLP-1, while 44.3% used ≥ 2. The most frequent con-
comitant medication classes were biguanide (61.1%) and sulfonylurea (30.4%). 
Co-occurring cardiovascular medications (87.2% in the pre-index; 81.1% at index) 
were commonly used, as were lipid-lowering medications, specifically (72.6% in 
the pre-index; 62.9% at index). Over the variable-length follow-up, mean(SD) daily 
dose was 19.8(3.2)µg for exBID, 1.58(0.14)mg for LIRA. ConClusions: Treatment 
patterns varied among GLP-1 patients in Canada. Longer-term data would be use-
ful to further elucidate practice patterns.
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objeCtives: 1)Compare demographic and clinical characteristics and treat-
ment patterns of anti-vascular endothelial growth factor (VEGF) (bevacizumab, 
ranibizumab, pegaptanib) and laser therapies among diabetic macular edema 
(DME) patients; 2)Determine predictors of switching and anti-VEGF therapy initia-
tion. Methods: A retrospective cohort analysis was conducted with Texas Medicaid 
medical claims (1/1/08-12/31/12) for patients who were: 18- 63 years, continuously 
enrolled one year pre- and post-index, diagnosed with DME and treated with anti-
VEGF or laser. Treatment patterns included treatment frequency and switching 
between anti-VEGF and laser. Logistic regression was used to predict switching 
and initiation of anti-VEGF while controlling for demographic (age, gender, race) 
and clinical characteristics (visual impairment, Charlson Comorbidity Index (CCI), 
number of unique prescriptions). Results: DME patients (N= 2158) were 54.7±7.8 
years, 62.7% female and 58.3% Hispanic. 9.7% were visually impaired, CCI mean 
score was 6.5±3.2 and patients were on 2.6±3.2 unique prescriptions. A higher 
(p= 0.03) percentage of females were treated with laser (63.7%) compared to anti-
VEGF (57.6%). Anti-VEGF users (1.9±3.0) had fewer (p< 0.0001) prescriptions compared 
to laser (2.7±3.2). Laser was most commonly used (84.4%); however, anti-VEGF use 
increased from 12.6% in 2009 to 23.8% in 2011 (p< 0.0001). Patients received 2.2±1.4 
laser surgeries compared to 2.4±1.8 anti-VEGF injections. Switching from laser to 
anti-VEGF was 9.6%, while anti-VEGF to laser was 42.4%. Logistic regression showed 
that switchers were more likely to be Hispanic (OR= 1.442;95%CI= 1.053-1.975), male 
(OR= 1.333;95%CI= 1.043-1.703), have fewer prescriptions (OR= 0.946;95%CI= 0.907-
0.986) and less likely to have no visual impairment (OR= 0.620;95%CI= 0.434-0.885). 
Anti-VEGF initiators were likely to be Hispanic (OR= 1.402;95%CI= 1.032-1.906), have 
fewer prescriptions (OR= 0.909;95%CI= 0.871-0.950) and initiate in 2011 vs. 2009 
(OR= 2.298;95%CI= 1.722-3.065). ConClusions: Conclusions: Although anti-VEGF 
use in increasing, laser therapy is still more prevalent. Also, slightly over 40% of 
patients who initiated on anti-VEGF switched to laser after the first treatment. 
Additional research should be conducted to determine factors associated with this 
high rate of switching.
without previous injection experience were more likely to use a support program. 
For 67% of patients using any program, the corresponding medication was the first 
injectable taken. The proportion who rated their program as extremely useful (6 
or 7 on a 7-point scale) was 57% for BSS, 54% for VC, and 68% for LC. Overall, 49% 
reported using their program for 6 months or longer. Length of utilization was high-
est for LC with 31% reporting using the program for ≥ 1 yr. The program components 
most commonly used were educational materials (used by 75%), coupons (43%), 
telephonic support (31%), and medication reminders (8%). Use of educational mate-
rials was highest for LC, use of coupons was highest for VC, and use of telephonic 
support and reminders was highest for BSS. ConClusions: Although the minority 
of patients reported using these patient-support programs, those who did use them 
reported high levels of satisfaction and relatively long engagement.
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objeCtives: The aim of this claims-based data analysis was to describe the inpa-
tient/outpatient care of German T2DM patients and to determine which subgroups 
could be differentiated in terms of the achieved T2DM-related treatment results, 
the underlying comorbidities, and the achieved comorbidity-related treatment 
results. Methods: We included all T2DM patients insured by one large sickness 
fund in 2010/2011. We defined 12 different T2DM patient subgroups according to 
observed HbA1C, blood pressure, and Charlson Comorbidity Index (CCI). For each 
subgroup, available sociodemographic information, HbA1C, blood pressure, CCI, BMI, 
kidney status, and previous micro- and macrovascular events the patients expe-
rienced were reported. Furthermore, outpatient/inpatient as well as medication 
treatment was described. T2DM related events leading to acute hospitalisations 
were reported for all subgroups. Results: We included 394,828 T2DM-patients in 
our analysis (age 73.10 years; CCI 6.86); for 228,703 patients detailed laboratory 
data as basis for subgroup classification were available. For 4.5% of the patients, 
a HbA1C> 9% was observed. Across all patient subgroups, a total of 21,833 of the 
patients involved were affected by a T2DM-related event; the risk was 5.53% per 
patient year; 1.74% of the patients suffered from more than one event. Most frequent 
event types were hospitalisation with T2DM as primary diagnosis (2.39%), vascu-
lar interventions/stent implantations (1.92%), and ischaemic stroke (1.19%). There 
were significant differences between the observed subgroups in terms of T2DM-
related event risk; belonging to a specific subgroup is an independent predictor of 
the event risk. ConClusions: Overall, our data indicate that the typically treated 
T2DM patient has a number of comorbidities and thus treatment focused solely on 
T2DM is neither possible nor clinically meaningful. Particularly those patients who 
reached HbA1C goals, but had also achieved relevant additional treatment goals 
reached low yearly T2DM event rates whereas subgroups failing to achieve one or 
several treatment goals are facing much higher event risks.
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objeCtives: Diabetes mellitus (DM) is one of the diseases with the largest health 
care expenditures, with an estimated cost of $245 billion in 2012. We assessed US 
Food and Drug Administration (FDA) approval trends and manufacturer listed prices 
at approval of diabetes medications. Methods: Regulatory data were derived from 
the FDA website and average wholesaler price (AWP) per unit from the RedBook 
(Truven Health Analytics, Inc.). Descriptive statistical methods were used in the 
analysis. Results: There were 104 medications approved for DM as of January 1, 
2014. Among them, 53% were insulins and 47% oral antidiabetes drugs (OAD). The 
FDA designated 8 orphan indications for diabetes, but not orphan designations were 
approved to date. The number of insulin approvals was higher during the 1980’s and 
the number of OAD approvals was higher between 2000 and 2009. The rate of market 
discontinuation was 75.0% for insulins and 18.4% for OAD. There were a total of 23 
OADs with generic market competition. The mean time from new drug application 
approval to abbreviated new drug application approval was 15.4 years. Mean AWP 
unit prices were $1.25 for insulins and $0.30 for OADs in the 1980’s, and increased 
to $6.45 and $12.73, respectively in the 2000’s. From the 1980s to the 2000s, OAD 
manufacturer prices at approval increased by 42 times and insulin prices increased 
by 5 times. In comparison, the consumer price index increased 2.8 times during the 
same period. ConClusions: OAD products represented the largest percentage of 
new products approved for diabetes after 2000. In contrast, the number of insulin 
approvals decreased during the same period. There were not orphan approvals 
indicating the high prevalence of DM in the US. Manufacturer listed prices increased 
at higher pace than the inflation during the study period.
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objeCtives: NICE technology appraisal TA151 (Continuous subcutaneous insulin 
infusion [CSII] for the treatment of diabetes mellitus) was issued in July 2008, replac-
ing TA57 from February 2003 and recommending uptake of CSII pumps in (1) adults 
with type 1 diabetes mellitus (T1DM) who fail to reduce HbA1c < 8.5%, or disabling 
hypoglycaemia using multiple daily injections (MDI), (2) and children without requir-
ing previous MDI-failure. CSII uptake in the UK rose to 4% between 2003–2008 and 
